3.3 CYP2C19 And CBD Exposure The Epidiolex FDA pharmacology review reported an unexpected trend in increasing CBD concentrations from CYP2C19 IMs (lowest exposure) ≤ NMs≤RMs (highest exposure) [ 2 ].
← all excerpts
Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers.
1
—
—